CEACAM1 and neoplasm: In our in vivo syngeneic tumor models, CT26, MBT2 and A20, anti-CEACAM1 Ab CC1 administered as a single agent therapy or in combination with an anti-PD-1 mAb (muDX400), provided no tumor growth inhibition.